Triple therapy aims to wipe out colorectal cancer before surgery

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Voluntarily signs written informed consent before screening. * Male or female, aged 18 years or older. * Has at least one measurable lesion according to RECIST version 1.1. * ECOG performance status score of 0 to 1. * Histologically or pathologically confirmed colorectal adenocarcinoma with no prior antitumor treatment, staged as cT3/cT4N+M0 locally advanced colorectal cancer according to the AJCC/UICC 8th edition based on contrast-enhanced CT or MRI, with colonoscopy and/or diagnostic laparoscopy if clinically indicated. * Planned to undergo surgery after neoadjuvant therapy according to clinical staging. * Expected survival of more than 3 months. * Adequate major organ function, meeting all of the following criteria: * Hematology: neutrophil count ≥1.5 × 10\^9/L, platelet count ≥100 × 10\^9/L, hemoglobin ≥90 g/L, and white blood cell count ≥3.5 × 10\^9/L, without blood transfusion, granulocyte colony-stimulating factor, or other hematopoietic growth factors within 14 days before screening. * Hepatic function: ALT and AST ≤2.5 × upper limit of normal, and total bilirubin ≤1.5 × upper limit of normal, or ≤3 × upper limit of normal for patients with Gilbert syndrome. * Renal function: serum creatinine ≤1.5 × upper limit of normal or creatinine clearance ≥60 mL/min. * Coagulation function: activated partial thromboplastin time, international normalized ratio, and prothrombin time ≤1.5 × upper limit of normal. Exclusion Criteria: * Prior treatment with any antitumor therapy, including chemotherapy, radiotherapy, hormonal therapy, or molecular targeted therapy. * Prior immunotherapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or any other antibody or drug targeting T-cell co-stimulation or immune checkpoint pathways. * History of another malignancy within 5 years or concurrent malignancy, except cured carcinoma in situ of the cervix, non-melanoma skin cancer, or other malignancy treated with curative intent with no evidence of disease for at least 5 years. * Pre-existing peripheral neuropathy of grade 2 or higher according to NCI-CTCAE version 5.0. * Known active central nervous system metastasis and/or carcinomatous meningitis. * History of severe hypersensitivity reaction to any component of a product or formulation similar to the study PD-1 antibody, or known severe hypersensitivity reaction to other monoclonal antibodies, oxaliplatin, capecitabine, or related compounds, defined as NCI-CTCAE version 5.0 grade 3 or higher. * Known history of hereditary bleeding disorder or coagulation disorder associated with bleeding risk. * Major surgery within 4 weeks before enrollment. * Has not recovered from complications of prior surgery to grade 1 or lower according to CTCAE version 5.0, except alopecia and fatigue. * Requires immunosuppressive medication within 2 weeks before enrollment or during the study, except intranasal, inhaled, topical, or local steroid injections; systemic corticosteroids at physiological doses equivalent to prednisone ≤10 mg/day; or short-term use of steroids for prevention or treatment of non-autoimmune allergic conditions for no more than 7 days. * Active autoimmune disease or history of autoimmune disease with potential recurrence. * Known history of interstitial lung disease or non-infectious pneumonitis. * Known history of active tuberculosis. * History of human immunodeficiency virus infection, other acquired or congenital immunodeficiency disease, organ transplantation, or stem cell transplantation. * Positive hepatitis B surface antigen with HBV DNA ≥10\^4 copies/mL or ≥2000 IU/mL at screening, or active hepatitis C defined as positive HCV antibody with HCV RNA above the lower limit of detection. * Active or uncontrolled infection requiring systemic treatment within 2 weeks before enrollment. * Receipt of a live viral vaccine within 4 weeks before enrollment. * Intestinal obstruction, inflammatory bowel disease, extensive intestinal resection with chronic diarrhea, Crohn's disease, ulcerative colitis, or chronic diarrhea. * Breastfeeding, or planning pregnancy during treatment and within 6 months after completion of treatment. * Unwillingness to use effective contraception during treatment and within 6 months after completion of treatment, including male participants capable of fathering a child, female participants, and their male partners. * Any other condition that, in the investigator's judgment, may affect protocol compliance or assessment of study endpoints and makes the participant unsuitable for this study.